LQDA — Liquidia Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819576 ·
Last close
$56.73
Market Cap
$5.11B
52W High
$93.61
52W Low
$22.31
ADV30
4,133,583
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 225,300,000 | 210,523,000 | 126,230,000 | -236,328,000 | 682,942,000 | 396,091,000 | 708,376,000 |
| Jun 2026 | 171,679,000 | 160,129,000 | 85,517,000 | 74,722,000 | 521,918,000 | 284,181,000 | 326,804,000 |
| Mar 2026 | 132,865,000 | 121,013,000 | 61,504,000 | 52,862,000 | 401,533,000 | 222,786,000 | 292,954,000 |
| Dec 2025 | 92,021,000 | 84,966,000 | 19,787,000 | 14,555,000 | 327,934,000 | 190,680,000 | 283,186,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$324,156,000
Investing CF
$-36,005,000
Financing CF
$-49,556,000
CapEx
$-36,005,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.23
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-735,057,000
Inventory
$36,174,000
Receivables
$116,749,000
ST Investments
—
EBIT TTM
$-90,796,000
Pretax Income TTM
$-113,365,000
Interest Exp TTM
$22,569,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$621,865,024
EBITDA
$294,200,000
Free Cash Flow
$535,596,992
Enterprise Value
$4,945,677,824
Total Cash
$396,091,008
Total Debt
$168,758,000
Shares Out
90,106,442
Trailing EPS
$-1.05
Book Value
$-0.28
ROE
131.8%
ROA
38.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 158,320,000 | -51,376,000 | -68,924,000 | 327,934,000 | 283,186,000 | 44,748,000 | -35,686,000 |
| Dec 2024 | 13,996,000 | -121,294,000 | -128,291,000 | 230,313,000 | 150,935,000 | 79,378,000 | -93,422,000 |
| Dec 2023 | 17,488,000 | -73,384,000 | -78,502,000 | 118,332,000 | 71,039,000 | 47,293,000 | -41,564,000 |
| Dec 2022 | 15,935,000 | -38,770,000 | -41,015,000 | 129,198,000 | 38,776,000 | 90,422,000 | -28,588,000 |
TTM Snapshot
Revenues TTM
$450,907,000
NetIncome TTM
$138,606,000
OpCashFlow TTM
—
Assets (Latest)
$521,918,000
Forward EPS
$3.44
Max Pain — expiry 2026-12-18
max pain strike: $45.00 · spot: $56.40 · call oi: 13,441 · put oi: 2,753
Expected Move to 2026-12-18:
±$8.30
(14.72%) —
implied range
$48.10 –
$64.70
· ATM straddle on $57.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | $5.04B | $60.36 | — |
| MANE | Veradermics, Inc | $5.30B | $125.64 | — |
| TVTX | Travere Therapeutics, Inc. | $4.91B | $51.10 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.90B | $86.98 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
News headlines (Yahoo Finance, 1h cache)
Will Revenue Growth And Wider Losses Change Liquidia (LQDA) Stock Narrative
2026-11-18 01:11 · Yahoo
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
2026-11-11 16:38 · Yahoo
Nvidia downgraded, Mercury Systems upgraded: Wall Street's top analyst calls
2026-11-11 14:45 · Yahoo
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
2026-11-11 14:00 · Yahoo
Liquidia (LQDA) Q3 2026 Earnings Call Transcript
2026-11-10 19:00 · Yahoo
Liquidia Q3 Earnings Call Highlights
2026-11-10 18:15 · Yahoo
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
2026-11-10 11:40 · Yahoo
Liquidia Corporation Reports Third Quarter 2026 Financial Results
2026-11-10 11:30 · Yahoo
Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power
2026-11-10 03:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.